TZD drug pioglitazone becomes second-ever diabetes drug to reduce heart disease and first to reduce strokes. Who might this benefit most? Continue Reading »
The latest research in type 1 diabetes, type 2 diabetes, prediabetes, and beyond. Here you’ll find information on experimental therapies, new data and results, and scientific findings.
TZD drug pioglitazone becomes second-ever diabetes drug to reduce heart disease and first to reduce strokes. Who might this benefit most? Continue Reading »
Incredible presentation from CEO Derek Rapp on the state of the foundation. Plus, updates on the Bionic Pancreas and ViaCyte! Continue Reading »
A new study from Dr. Doug Melton’s team provides hope for the future of stem cell treatment in diabetes. But there’s still a long way to go. Continue Reading »
When might this product reach the market? Continue Reading »
A 38% decrease in cardiovascular death is exciting, but our work is nowhere near done. Continue Reading »
Breaking news from Stockholm, Sweden, where our team is on the ground at the European Association for the Study of Diabetes (EASD) Conference – one of the largest diabetes conferences of the year. Lilly/BI just announced the groundbreaking results from their major clinical trial on Jardiance... Continue Reading »